Almirall (OTCMKTS:LBTSF – Get Free Report) will likely be issuing its resultson Friday, July 24th. Analysts expect the company to announce earnings of $0.1485 per share and revenue of $357.4080 million for the quarter.
Almirall Stock Performance
Shares of OTCMKTS LBTSF opened at $15.35 on Thursday. Almirall has a 52 week low of $13.36 and a 52 week high of $15.47. The firm has a 50-day moving average price of $15.35 and a 200 day moving average price of $15.37.
Almirall Company Profile
Almirall is a research-driven pharmaceutical company headquartered in Barcelona, Spain. Founded in 1943, the firm has evolved into a specialist in dermatology, dedicating its efforts to understanding and treating a range of inflammatory and chronic skin conditions. Over the decades, Almirall has built a reputation for its targeted R&D approach and its commitment to improving patient outcomes in dermatological care.
The company’s core activities span the research, development, manufacturing and marketing of prescription therapies for skin diseases.
Recommended Stories
- Five stocks we like better than Almirall
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Almirall Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Almirall and related companies with MarketBeat.com's FREE daily email newsletter.
